“Trial in Progress: A Phase 3 Randomized Study of Low-Dose Intralesional Cemiplimab Versus Primary Surgery for Patients With Early-Stage Cutaneous Squamous Cell Carcinoma (CLEAR CSCC)”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 6, Nov. 2025, p. s689, https://doi.org/10.25251/cpgrax68.